{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:30:30Z","timestamp":1777487430176,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ijantimicag.2020.106002","type":"journal-article","created":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T07:46:13Z","timestamp":1588232773000},"page":"106002","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Revisiting aminocoumarins for the treatment of melioidosis"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0756-4859","authenticated-orcid":false,"given":"S.J.","family":"Willcocks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Cia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.F.","family":"Francisco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.W.","family":"Wren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106002_bib0001","article-title":"Melioidosis in Africa: time to uncover the true disease load","volume":"3","author":"Steinmetz","year":"2018","journal-title":"Trop Med Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106002_bib0002","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3201\/eid1109.050493","article-title":"Melioidosis, northeastern Brazil","volume":"11","author":"Rolim","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106002_bib0003","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1183\/09031936.03.00006203","article-title":"an important cause of pneumonia in residents of and travellers returned from endemic regions","volume":"22","author":"Melioidosis","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2020.106002_bib0004","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/jac\/dkh471","article-title":"Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents","volume":"54","author":"Thibault","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106002_bib0005","doi-asserted-by":"crossref","first-page":"15008","DOI":"10.1038\/nmicrobiol.2015.8","article-title":"Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis","volume":"1","author":"Limmathurotsakul","year":"2016","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106002_bib0006","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2217\/fmb.12.116","article-title":"Mechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis","volume":"7","author":"Schweizer","year":"2012","journal-title":"Future Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106002_bib0007","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1128\/AAC.00954-06","article-title":"Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis","volume":"51","author":"Zhou","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106002_bib0008","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1476-5381.2011.01250.x","article-title":"Novel classes of antibiotics or more of the same?","volume":"163","author":"Coates","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ijantimicag.2020.106002_bib0009","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/cid\/ciw593","article-title":"Economic incentives for antibacterial drug development: literature review and considerations from the Transatlantic Task Force on Antimicrobial Resistance","volume":"63","author":"Sciarretta","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106002_bib0010","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ijantimicag.2010.02.007","article-title":"Comparative efficacy of novobiocin and amoxicillin in experimental sepsis caused by \u03b2-lactam-susceptible and highly resistant pneumococci","volume":"35","author":"Rodriguez-Cerrato","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106002_bib0011","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1099\/00222615-6-3-293","article-title":"Bactericidal synergism of novobiocin and tetracycline against Pseudomonas pseudomallei","volume":"6","author":"Calabi","year":"1973","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106002_bib0012","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1128\/AAC.47.3.869-877.2003","article-title":"Resistance genes of aminocoumarin producers: two type II topoisomerase genes confer resistance against coumermycin A1 and clorobiocin","volume":"47","author":"Schmutz","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106002_bib0013","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1021\/id500013t","article-title":"A new-class antibacterial\u2014almost. Lessons in drug discovery and development: a critical analysis of more than 50 years of effort toward ATPase inhibitors of DNA gyrase and topoisomerase IV","volume":"1","author":"Bisacchi","year":"2015","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106002_bib0014","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/21505594.2019.1621649","article-title":"Galleria mellonella as a consolidated in vivo model hosts: new developments in antibacterial strategies and novel drug testing","volume":"10","author":"Cutuli","year":"2019","journal-title":"Virulence"},{"key":"10.1016\/j.ijantimicag.2020.106002_bib0015","article-title":"Recent advances in the use of Galleria mellonella model to study immune responses against human pathogens","volume":"4","author":"Pereira","year":"2018","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.ijantimicag.2020.106002_bib0016","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1128\/AAC.50.4.1136-1142.2006","article-title":"Structure\u2013activity relationships of aminocoumarin-type gyrase and topoisomerase IV inhibitors obtained by combinatorial biosynthesis","volume":"50","author":"Flatman","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106002_bib0017","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ijpharm.2018.12.036","article-title":"Co-former selection for co-amorphous drug\u2013amino acid formulations","volume":"557","author":"Kasten","year":"2019","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ijantimicag.2020.106002_bib0018","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ejpb.2013.03.014","article-title":"Amino acids as co-amorphous stabilizers for poorly water soluble drugs\u2014Part 1: preparation, stability and dissolution enhancement","volume":"85","author":"Lobmann","year":"2013","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.ijantimicag.2020.106002_bib0019","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/jps.3030490417","article-title":"Some pharmaceutical properties of novobiocin","volume":"49","author":"Mullins","year":"1960","journal-title":"J Am Pharm Assoc Am Pharm Assoc"},{"key":"10.1016\/j.ijantimicag.2020.106002_bib0020","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1096\/fj.12-225219","article-title":"Polymersome-mediated intracellular delivery of antibiotics to treat Porphyromonas gingivalis-infected oral epithelial cells","volume":"27","author":"Wayakanon","year":"2013","journal-title":"FASEB J"},{"key":"10.1016\/j.ijantimicag.2020.106002_bib0021","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1146\/annurev.bioeng.8.061505.095735","article-title":"Recent approaches to intracellular delivery of drugs and DNA and organelle targeting","volume":"8","author":"Torchilin","year":"2006","journal-title":"Annu Rev Biomed Eng"},{"key":"10.1016\/j.ijantimicag.2020.106002_bib0022","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0076-6879(00)27293-5","article-title":"Coumermycin-induced dimerization of GyrB-containing fusion proteins","volume":"327","author":"Farrar","year":"2000","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.ijantimicag.2020.106002_bib0023","first-page":"541","article-title":"Efficacy of coumermycin, ofloxacin and vancomycin against methicillin-resistant Staphylococcus aureus in vitro and in experimental infections of mice","volume":"267","author":"Hirschl","year":"1988","journal-title":"Zentralbl Bakteriol Mikrobiol Hyg A"},{"key":"10.1016\/j.ijantimicag.2020.106002_bib0024","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1099\/jmm.0.47596-0","article-title":"Burkholderia pseudomallei aerosol infection results in differential inflammatory responses in BALB\/c and C57Bl\/6 mice","volume":"57","author":"Tan","year":"2008","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106002_bib0025","first-page":"623","article-title":"Activity of selected antimicrobial agents against the Pseudomonas pseudomallei infection of mice","volume":"101","author":"Grunberg","year":"1970","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.ijantimicag.2020.106002_bib0026","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1128\/AAC.00382-15","article-title":"Kibdelomycin is a bactericidal broad-spectrum aerobic antibacterial agent","volume":"59","author":"Singh","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106002_bib0027","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.chembiol.2007.07.014","article-title":"Improved mutasynthetic approaches for the production of modified aminocoumarin antibiotics","volume":"14","author":"Anderle","year":"2007","journal-title":"Chem Biol"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920301606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920301606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T19:32:35Z","timestamp":1735673555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920301606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0924857920301606"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106002","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revisiting aminocoumarins for the treatment of melioidosis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106002"}}